Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2020
Sick of high drug prices, insurers join hospitals to make their own generic medications
23 January 2020 - Everyone complains about high drug prices. But hospitals — and now insurers — are trying to ...
Posted by Michael Wonder on 21 Jan 2020
European Commission approves Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are transplant eligible
20 January 2020 - Janssen announced today that the European Commission has granted marketing authorisation for Darzalex (daratumumab) in combination with ...
Posted by Michael Wonder on 21 Jan 2020
Jazz Pharmaceuticals receives EU marketing authorisation for Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea
20 January 2020 - Sunosi is the only licensed therapy in Europe for the treatment of excessive daytime sleepiness in adults ...
Posted by Michael Wonder on 20 Jan 2020
After 20 years of using economic evaluation, should NICE be considered a methods innovator?
13 January 2020 - NICE is only one of several organisations internationally that uses economic evaluation as part of decision ...
Posted by Michael Wonder on 20 Jan 2020
Talkin’ about a resolution: issues in the push for greater transparency of medicine prices
20 January 2020 - At the 2019 World Health Assembly, a significant new resolution was agreed by most countries to start ...
Posted by Michael Wonder on 20 Jan 2020
FDA delays decision on Intercept's NASH drug by three months
20 January 2020 - Action date pushed back to 26 June. ...
Posted by Michael Wonder on 20 Jan 2020
Patients still struggle to balance high costs of MS treatment, despite generic
20 January 2020 - Sometimes, the approval of a new generic drug offers more hype than hope for patients' wallets, ...
Posted by Michael Wonder on 20 Jan 2020
Novartis announces EU approval of Mayzent (siponimod) for adult patients with secondary progressive multiple sclerosis with active disease
20 January 2020 - Mayzent (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple ...
Posted by Michael Wonder on 20 Jan 2020
Lynparza regulatory submission granted priority review in the US for HRR-mutated metastatic castration-resistant prostate cancer
20 January 2020 - Submission based on PROfound, the first positive Phase III trial testing a targeted treatment in biomarker-selected ...
Posted by Michael Wonder on 20 Jan 2020
Ten recommendations to unlock the potential of big data for public health in the EU
20 January 2020 - The joint Big Data Task Force of EMA and the Heads of Medicines Agencies proposes ten ...
Posted by Michael Wonder on 20 Jan 2020
Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study
17 January 2020 - Failure to report the results of a clinical trial can distort the evidence base for clinical practice, ...
Posted by Michael Wonder on 20 Jan 2020
Fees and charges proposal 2020-21
20 January 2020 - The TGA is undertaking a consultation through its website to seek stakeholder's views on TGA’s proposed fees ...
Posted by Michael Wonder on 20 Jan 2020
Why cancelling your private health insurance could have unintended consequences
20 January 2020 - Nick Maconachie and Anna Dimeas have very different views on private health cover. ...
Posted by Michael Wonder on 20 Jan 2020
New fee website shows NSW pays up to 40 times more in out-of-pocket costs
20 January 2020 - Private health patients in NSW are paying up to 40 times more in out-of-pocket costs than ...
Posted by Michael Wonder on 20 Jan 2020
Sharing health care data with digital giants
16 January 2020 - Overcoming obstacles and reaping benefits while protecting patients. ...
Posted by Michael Wonder on 20 Jan 2020
New science strategy prepares regulatory scientists for the future
20 January 2020 - The Health Products Regulation Group in the Department of Health has published a new regulatory science ...